You are here: Industry Insights > PFS

News List

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes PharmaSources
October 15, 2024
BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.
BD Completes Study Investigating Performance of Glass Prefillable Syringes (PFS) in Deep Cold Storage B3Cnewswire
September 28, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, completed a preliminary study investigating the impact of deep cold storage (-20°C and -40°C) on glass PFS.
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years prnasia
December 03, 2020
BD, a leading global medical technology company, announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems ...
MSD's Keytruda misses advanced bladder cancer goal pharmatimes
June 16, 2020
MSD's Keytruda (pembrolizumab) has failed to hit key goals in a trial assessing its potential as a first-line treatment for bladder cancer.
WuXi Biologics Completes PFS Filling at Robotic Aseptic Filling Facility contractpharma
April 30, 2020
Successfully completes the filling of two batches of pre-filled syringes using robotic filling isolator.
Bristol-Myers Squibb Announces Opdivo Glioblastoma Study Does Not Meet PFS Primary Endpoint americanpharmaceuticalreview
September 06, 2019
Bristol-Myers Squibb announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard ...
AZ' Calquence shows PFS benefit in CLL patients pharmatimes
June 18, 2019
AstraZeneca has presented detailed data showing that Calquence (acalabrutinib) significantly prolonged progression free survival (PFS) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).
Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer pharmaceutical-technology
June 05, 2019
AstraZeneca and Merck have announced that Lynparza (olaparib) demonstrated significant improvement in progression-free survival (PFS), compared to placebo, in germline BRCA-mutated metastatic .adenocarcinoma of the pancreas.
Lilly’s Cyramza hits first-line NSCLC trial targets pharmatimes
March 14, 2019
Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.
Trial Shows XTANDI Significantly Improved Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer americanpharmaceuticalreview
February 13, 2019
Pfizer and Astellas Pharma announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).....

Previous page 1 2 Next page